Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets
Rhea-AI Filing Summary
Evolus, Inc., through its subsidiary Evolus Pharma B.V., has amended its license, supply and distribution agreement with Symatese Aesthetics to add exclusive rights to commercialize the Estyme® injectable hyaluronic acid gel portfolio in Canada, Australia and New Zealand.
As consideration, Evolus Europe will pay €920,000 in upfront signing payments and up to an additional €1.38 million tied to regulatory approvals, while Symatese remains responsible, at its expense, for development and regulatory activities. The initial term in each new territory is 15 years from first regulatory approval, with automatic five-year renewals. Evolus targets commercialization in 2028, citing a combined neurotoxin and dermal filler market of about $500 million annually across these countries and expects the arrangement, including product transfer pricing and a mid-single digit royalty on net sales, to be accretive to international gross margins.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Upfront signing payments: €920,000
Regulatory milestone payments: €1.38 million
Initial term per new territory: 15 years
+5 more
8 metrics
Upfront signing payments
€920,000
Consideration for additional Estyme® rights in Canada, Australia and New Zealand
Regulatory milestone payments
€1.38 million
Additional payments payable upon receipt of certain regulatory approvals
Initial term per new territory
15 years
Runs from first applicable regulatory approval for each added territory
Renewal term length
5 years
Automatic successive renewal periods after the initial 15-year term
Target market size
$500 million annually
Combined neurotoxin and dermal filler market in Canada, Australia and New Zealand
Neurotoxin share of market
60%
Approximate portion of the $500 million market attributable to neurotoxins
Dermal filler share of market
40%
Approximate portion of the $500 million market attributable to dermal fillers
Expected commercialization year
2028
Planned timing to launch Estyme® in Canada, Australia and New Zealand
Key Terms
License, Supply and Distribution Agreement, hyaluronic acid (HA) gels, Cold-X® technology, total addressable market, +1 more
5 terms
License, Supply and Distribution Agreement regulatory
"entered into an amendment to the License, Supply and Distribution Agreement"
hyaluronic acid (HA) gels medical
"Estyme® branded injectable hyaluronic acid (HA) gels in those territories"
Cold-X® technology technical
"The Estyme® collection features injectable HA gels utilizing Symatese’s innovative Cold-X® technology"
total addressable market financial
"represent a total addressable market of approximately $500 million annually"
Total addressable market is the total potential sales opportunity for a product or service if it were to reach every possible customer. It helps investors understand the maximum size of the market and the growth potential for a business. Think of it as the entire pie available to be shared, indicating how big the opportunity could be.
royalty financial
"pay a mid-single digit royalty based on net sales"
A royalty is a payment made to the owner of a resource or asset—such as a patent, mineral rights, or creative work—whenever others use or profit from it. For investors, royalties provide a steady stream of income without owning the entire asset, similar to earning a small commission each time a product is sold or a service is used. This makes royalties an important factor in valuing certain types of investments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What agreement did Evolus (EOLS) expand with Symatese?
Evolus expanded its existing License, Supply and Distribution Agreement with Symatese Aesthetics, granting Evolus Europe exclusive rights to commercialize the Estyme® injectable hyaluronic acid gels in Canada, Australia, and New Zealand, in addition to territories already covered under the original December 20, 2023 agreement.
Which new territories are covered in Evolus (EOLS) Estyme® expansion?
The amendment grants Evolus Europe exclusive Estyme® rights in Canada, Australia, and New Zealand. This creates a consistent multi-product platform in every market where Evolus currently sells Jeuveau® and Nuceiva®, aligning its neurotoxin and dermal filler offerings across its global commercial footprint.
What payments will Evolus (EOLS) make for the new Estyme® rights?
Evolus Europe will pay €920,000 in upfront signing payments and up to an additional €1.38 million upon achievement of specified regulatory approvals. Evolus will also purchase product at an agreed transfer price and pay a mid-single digit royalty on net sales in the licensed territories.
How large is the target market for Evolus (EOLS) in Canada, Australia and New Zealand?
Evolus cites a combined annual total addressable market of approximately $500 million for neurotoxin and dermal filler products across Canada, Australia, and New Zealand, with about 60% attributable to neurotoxins and 40% to dermal fillers in these injectable aesthetics categories.
When does Evolus (EOLS) expect to commercialize Estyme® in the new territories?
Evolus expects to begin commercializing the Estyme® injectable hyaluronic acid gel collection in 2028, subject to applicable regulatory approvals and review processes in Canada, Australia, and New Zealand. The initial term in each territory runs 15 years from the first regulatory approval, with automatic five-year renewals.
Who is responsible for regulatory approvals under the Evolus (EOLS) Symatese amendment?
Symatese Aesthetics will remain responsible, at its expense, for product development, manufacturing, clinical support, and all regulatory activities needed to obtain and maintain marketing approvals in the licensed territories, while Evolus focuses on commercialization through its existing international commercial infrastructure.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(949 ) 284-4555
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
(Nasdaq Global Market) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01 Entry into a Material Definitive Agreement.
Symatese License Amendment - Addition of Australia, New Zealand and Canada
On August 3, 2026, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”), and Symatese Aesthetics S.A.S. (“Symatese”) entered into an amendment (the “Amendment”) to the License, Supply and Distribution Agreement dated December 20, 2023 (the “Agreement”), which the Company previously disclosed in a Current Report on Form 8-K filed on December 20, 2023.
The Amendment expands the territory covered by the Agreement to include (i) Canada and (ii) Australia and New Zealand combined, and grants Evolus Europe exclusive rights to commercialize and distribute the full line of Estyme® branded injectable hyaluronic acid gels in those territories. As consideration for the additional rights, Evolus Europe is required to pay €920,000 in upfront signing payments and up to an additional €1.38 million upon receipt of certain regulatory approvals. Symatese will be responsible, at its expense, for the development and regulatory activities required to obtain and maintain regulatory approvals in the additional territories.
The initial term for each new territory is 15 years from the first applicable regulatory approval and will automatically renew for successive five-year terms, subject to the terms of the Agreement.
The foregoing is a summary of the terms of the Amendment and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Item 7.01 Regulation FD Disclosure.
On August 4, 2026, the Company issued a press release announcing the execution of the Amendment. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |||||||
| 99.1 | Press Release of Evolus, Inc., dated August 4, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolus, Inc. | ||||||||
Dated: August 4, 2026 | /s/ David Moatazedi | |||||||
David Moatazedi | ||||||||
President and Chief Executive Officer | ||||||||
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets
Further leverages Evolus’ international commercial infrastructure to support long-term profitable growth
NEWPORT BEACH, Calif., August 4, 2026 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced “esteem”) collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand.
With this agreement and expected commercialization in 2028, Evolus will hold exclusive rights to commercialize its injectable HA gel portfolio in every market where it currently markets Jeuveau® and Nuceiva®, establishing a consistent multi-product commercial platform across its global business.
The agreement further expands Evolus’ long-standing partnership with Symatese and strengthens the company’s international injectable HA gel portfolio by extending Estyme®, currently marketed in the United States under the brand name Evolysse®, into three additional attractive aesthetic markets. Upon regulatory approval, Evolus expects to commercialize the full Estyme® collection across Canada, Australia, and New Zealand, complementing its existing Nuceiva® neurotoxin franchise. Together, the neurotoxin and dermal filler markets across Canada, Australia, and New Zealand represent a total addressable market of approximately $500 million annually, with approximately 60% attributable to neurotoxins and 40% to dermal fillers.
“The addition of Canada, Australia and New Zealand is the final step that allows Evolus to offer the portfolio of Nuceiva® and Estyme® in every international market where we compete,” said David Moatazedi, President and Chief Executive Officer of Evolus. “From the beginning, our vision has been to provide customers with a complementary portfolio of best-in-class injectable products that can address the range of aesthetic patient needs. This alignment of our portfolio ensures we can deliver a consistent Evolus experience, strengthens our competitive position, and allows us to maximize the long-term value of the commercial platform we have built.”
Neurotoxins and HA dermal fillers are the two largest categories in injectable aesthetics and are increasingly used together as part of comprehensive facial treatment plans. The Estyme® collection features injectable HA gels utilizing Symatese’s innovative Cold-X® technology that is designed to preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results. By expanding Estyme® into Canada, Australia, and New Zealand, Evolus expects to enhance its value
proposition by providing customers with complementary injectable products through an established commercial organization, creating greater scale across its international business.
Under the terms of the agreement, Symatese will remain responsible for product development, manufacturing, clinical support, and regulatory activities required to obtain and maintain marketing approvals within the licensed territories. Evolus will make an upfront payment to Symatese along with additional payments tied to the achievement of specified regulatory approval milestones. Evolus will also purchase product from Symatese at an agreed transfer price and pay a mid-single digit royalty based on net sales. The agreement is expected to be accretive to Evolus’ international gross margins while leveraging the company’s existing commercial organization, digital platform, and distribution infrastructure across these markets. Commercialization of Estyme® in Canada, Australia, and New Zealand is expected in 2028, subject to applicable regulatory approvals and review processes.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future or anticipated events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company’s forward-looking statements include, but are not limited to, statements related to the anticipated benefits of the licensing and distribution agreement with Symatese; the planned development, regulatory approval and commercialization of the Estyme® collection in Canada, Australia, and New Zealand; the size of the injectable HA market in Canada, Australia, and New Zealand, and the expected impact on the company's financial results and profitability.
The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, our reliance on consumer discretionary spending, unfavorable global economic conditions including trade
disputes, tariffs and regulatory actions on imports, uncertainties related to customer and consumer adoption of Jeuveau® and Estyme®/Evolysse®, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse® Hyaluronic Acid (HA) gels in the U.S. and Estyme® HA gels outside the U.S., our ability to maintain regulatory approvals of Jeuveau® and Evolysse® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse® HA gel products in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the Securities and Exchange Commission on or about May 4, 2026. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.
Jeuveau®, Nuceiva®, and Evolysse® are registered trademarks of Evolus, Inc.
Estyme® and Cold-X® are registered trademarks of Symatese Aesthetics S.A.S.
Profhilo® is a registered trademark of IBSA Institut Biochimique SA.
###
Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com